Vitamin D: Cardiovascular effects and vascular calcification

Vitamin D

Volumn , Issue , 2011, Pages 1403-1426

  Towler, Dwight A ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884778187     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10073-3     Document Type: Chapter

References (265)

1. Wang T.J., Pencina M.J., Booth S.L., Jacques P.F., Ingelsson E., Lanier K., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
2. Mensah G.A., Brown D.W. An overview of cardiovascular disease burden in the United States. Health Aff. (Millwood.) 2007, 26:38-48.
3. Lavie C.J., Milani R.V., Ventura H.O. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J. Am. Coll. Cardiol. 2009, 53:1925-1932.
4. van Etten E., Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J. Steroid Biochem. Mol. Biol. 2005, 97:93-101.
5. Alborzi P., Patel N.A., Peterson C., Bills J.E., Bekele D.M., Bunaye Z., et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008, 52:249-255.
6. Husain K., Ferder L., Mizobuchi M., Finch J., Slatopolsky E. Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am. J. Nephrol. 2009, 29:465-472.
7. Moe S.M., Chen N.X. Mechanisms of vascular calcification in chronic kidney disease. J. Am. Soc. Nephrol. 2008, 19:213-216.
8. L.E. Clark, I. Khan, Outcomes in CKD: what we know and what we need to know. Nephron. Clin. Pract. 114 (2009) c95-c102.
9. de Bie M.K., van Dam B., Gaasbeek A., van Buren M., van Erven L., Bax J.J., et al. The current status of interventions aiming at reducing sudden cardiac death in dialysis patients. Eur. Heart J. 2009, 30:1559-1564.
10. Kanbay M., Turgut F., Covic A., Goldsmith D. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence. J. Nephrol. 2009, 22:598-609.
11. J.C. Marrs, J.J. Saseen, Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis, Pharmacotherapy 30 (2010) 823-829.
12. V.G. Athyros, E.K. Mitsiou, K. Tziomalos, A. Karagiannis, D.P. Mikhailidis, Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opin. Pharmacother. 11 (2010) 723-730.
13. Hendy G.N., Hruska K.A., Mathew S., Goltzman D. New insights into mineral and skeletal regulation by active forms of vitamin D. Kidney Int. 2006, 69:218-223.
14. K.A. Hruska, E.T. Choi, I. Memon, T.K. Davis, S. Mathew, Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr. Nephrol. 25 (2009) 769-778.
15. Palmer S.C., McGregor D.O., Craig J.C., Elder G., Macaskill P., Strippoli G.F. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane. Database Syst. Rev. 2009, CD005633.
16. Lartaud-Idjouadiene I., Lompre A.M., Kieffer P., Colas T., Atkinson J. Cardiac consequences of prolonged exposure to an isolated increase in aortic stiffness. Hypertension 1999, 34:63-69.
17. Price P.A., Faus S.A., Williamson M.K. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler. Thromb. Vasc. Biol. 2000, 20:317-327.
18. Wallin R., Wajih N., Greenwood G.T., Sane D.C. Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med. Res. Rev. 2001, 21:274-301.
19. Price P.A., June H.H., Buckley J.R., Williamson M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1610-1616.
20. Essalihi R., Dao H.H., Yamaguchi N., Moreau P. A new model of isolated systolic hypertension induced by chronic warfarin and vitamin K1 treatment. Am. J. Hypertens. 2003, 16:103-110.
21. Murphy M.J. Rodenticides. Vet. Clin. North Am. Small. Anim. Pract. 2002, 32:469-484. viii.
22. Shroff R., Egerton M., Bridel M., Shah V., Donald A.E., Cole T.J., et al. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J. Am. Soc. Nephrol. 2008, 19:1239-1246.
23. Heaney R.P. The vitamin D requirement in health and disease. J. Steroid Biochem. Mol. Biol. 2005, 97:13-19.
24. McGonigle R.J., Timmis A.D., Keenan J., Jewitt D.E., Weston M.J., Parsons V. The influence of 1 alpha-hydroxycholecalciferol on left ventricular function in end-stage renal failure. Proc. Eur. Dial. Transplant. Assoc. 1981, 18:579-585.
25. Chavan C.B., Sharada K., Rao H.B., Narsimhan C. Hypocalcemia as a cause of reversible cardiomyopathy with ventricular tachycardia. Ann. Intern. Med. 2007, 146:541-542.
26. Avsar A., Dogan A., Tavli T. A rare cause of reversible dilated cardiomyopathy: hypocalcemia. Echocardiography 2004, 21:609-612.
27. Tziomalos K., Kakavas N., Kountana E., Harsoulis F., Basayannis E. Reversible dilated hypocalcaemic cardiomyopathy in a patient with primary hypoparathyroidism. Clin. Endocrinol. (Oxf.) 2006, 64:717-718.
28. Roy R., El-Matary W., Gladman G., Isherwood D. Dilated cardiomyopathy and adipic aciduria in nutritional rickets. Pediatr. Emerg. Care 2006, 22:175-176.
29. J.K. Sung, J.Y. Kim, D.W. Ryu, J.W. Lee, Y.J. Youn, B.S. Yoo, A case of hypocalcemia-induced dilated cardiomyopathy. J. Cardiovasc. Ultrasound 18 25-27.
30. S. Verma, A. Khadwal, K. Chopra, M. Rohit, S. Singhi, Hypocalcemia nutritional rickets: a curable cause of dilated cardiomyopathy. J. Trop. Pediatr. doi: 10.1093/tropej/fmq044.
31. B.G. Kim, S.K. Chang, S.M. Kim, J.S. Hwang, J.W. Jung, Dilated cardiomyopathy in a 2 month-old infant: a severe form of hypocalcemia with vitamin d deficient rickets. Korean Circ. J. 40 (2010) 201-203.
32. Brown J., Nunez S., Russell M., Spurney C. Hypocalcemic rickets and dilated cardiomyopathy: case reports and review of literature. Pediatr. Cardiol. 2009, 30:818-823.
33. Maiya S., Sullivan I., Allgrove J., Yates R., Malone M., Brain C., et al. Hypocalcaemia and vitamin D deficiency: an important, but preventable, cause of life-threatening infant heart failure. Heart 2008, 94:581-584.
34. Weishaar R.E., Simpson R.U. Vitamin D3 and cardiovascular function in rats. J. Clin. Invest. 1987, 79:1706-1712.
35. Weishaar R.E., Simpson R.U. Involvement of vitamin D3 with cardiovascular function. II. Direct and indirect effects. Am. J. Physiol. 1987, 253:E675-E683.
36. Li Y.C., Pirro A.E., Amling M., Delling G., Baron R., Bronson R., et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc. Natl. Acad. Sci. USA 1997, 94:9831-9835.
37. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002, 110:229-238.
38. A. Benigni, P. Cassis, G. Remuzzi, Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol. Med. 2 (2010) 247-257.
39. Danilczyk U., Penninger J.M. Angiotensin-converting enzyme II in the heart and the kidney. Circ. Res. 2006, 98:463-471.
40. Zhou C., Lu F., Cao K., Xu D., Goltzman D., Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008, 74:170-179.
41. Thadhani R. Targeted ablation of the vitamin D 1alpha-hydroxylase gene: getting to the heart of the matter. Kidney Int. 2008, 74:141-143.
42. Yuan W., Pan W., Kong J., Zheng W., Szeto F.L., Wong K.E., et al. 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J. Biol. Chem. 2007, 282:29821-29830.
43. Kong J., Qiao G., Zhang Z., Liu S.Q., Li Y.C. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int. 2008, 74:1577-1581.
44. Simpson R.U., Hershey S.H., Nibbelink K.A. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J. Steroid Biochem. Mol. Biol. 2007, 103:521-524.
45. Bodyak N., Ayus J.C., Achinger S., Shivalingappa V., Ke Q., Chen Y.S., et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc. Natl. Acad. Sci. USA 2007, 104:16810-16815.
46. J. James, K. Hor, M.A. Moga, L.A. Martin, J. Robbins, Effects of myosin heavy chain manipulation in experimental heart failure. J. Mol. Cell Cardiol. 48 (2009) 999-1006.
47. Krenz M., Robbins J. Impact of beta-myosin heavy chain expression on cardiac function during stress. J. Am. Coll. Cardiol. 2004, 44:2390-2397.
48. James J., Martin L., Krenz M., Quatman C., Jones F., Klevitsky R., et al. Forced expression of alpha-myosin heavy chain in the rabbit ventricle results in cardioprotection under cardiomyopathic conditions. Circulation 2005, 111:2339-2346.
49. Xiang W., Kong J., Chen S., Cao L.P., Qiao G., Zheng W., et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E125-E132.
50. K. Kinouchi, A. Ichihara, M. Sano, G.H. Sun-Wada, Y. Wada, A. Kurauchi-Mito, et al., The (Pro)renin receptor/ATP6AP2 is essential for vacuolar H+-ATPase assembly in murine cardiomyocytes, Circ. Res. 107 (2010) 30-34.
51. Fyhrquist F., Saijonmaa O. Renin-angiotensin system revisited. J. Intern. Med. 2008, 264:224-236.
52. Kong J., Li Y.C. Effect of ANG II type I receptor antagonist and ACE inhibitor on vitamin D receptor-null mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:R255-R261.
53. A. Tomaschitz, S. Pilz, E. Ritz, T. Grammer, C. Drechsler, B.O. Boehm, Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin. Chim. Acta. 411 (2010) 1354-1360.
54. Tishkoff D.X., Nibbelink K.A., Holmberg K.H., Dandu L., Simpson R.U. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 2008, 149:558-564.
55. G. Zhao, R.U. Simpson, Interaction between vitamin D receptor with caveolin-3 and regulation by 1,25-dihydroxyvitamin D3 in adult rat cardiomyocytes. J. Steroid Biochem. Mol. Biol. 121 (2010) 159-163.
56. G. Zhao, R.U. Simpson, Membrane localization, Caveolin-3 association and rapid actions of vitamin D receptor in cardiac myocytes. Steroids 75 (2010) 555-559.
57. Green J.J., Robinson D.A., Wilson G.E., Simpson R.U., Westfall M.V. Calcitriol modulation of cardiac contractile performance via protein kinase C. J. Mol. Cell Cardiol. 2006, 41:350-359.
58. Grey A., Lucas J., Horne A., Gamble G., Davidson J.S., Reid I.R. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J. Clin. Endocrinol. Metab. 2005, 90:2122-2126.
59. Heaney R.P., Davies K.M., Chen T.C., Holick M.F., Barger-Lux M.J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am. J. Clin. Nutr. 2003, 77:204-210.
60. Zydowo M.M., Swierczynski J., Nagel G., Wrzolkowa T. The respiration and calcium content of heart mitochondria from rats with vitamin D-induced cardionecrosis. Biochem. J. 1985, 226:155-161.
61. Wrzolkowa T., Zydowo M. Ultrastructural studies on the vitamin D induced heart lesions in the rat. J. Mol. Cell Cardiol. 1980, 12:1117-1133.
62. Niederhoffer N., Bobryshev Y.V., Lartaud-Idjouadiene I., Giummelly P., Atkinson J. Aortic calcification produced by vitamin D3 plus nicotine. J. Vasc. Res. 1997, 34:386-398.
63. Norman P., Moss I., Sian M., Gosling M., Powell J. Maternal and postnatal vitamin D ingestion influences rat aortic structure, function and elastin content. Cardiovasc. Res. 2002, 55:369-374.
64. Hinek A., Botney M.D., Mecham R.P., Parks W.C. Inhibition of tropoelastin expression by 1,25-dihydroxyvitamin D3. Connect Tissue Res. 1991, 26:155-166.
65. Pierce R.A., Kolodziej M.E., Parks W.C. 1,25-Dihydroxyvitamin D3 represses tropoelastin expression by a posttranscriptional mechanism. J. Biol. Chem. 1992, 267:11593-11599.
66. Basalyga D.M., Simionescu D.T., Xiong W., Baxter B.T., Starcher B.C., Vyavahare N.R. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation 2004, 110:3480-3487.
67. Simionescu A., Philips K., Vyavahare N. Elastin-derived peptides and TGF-beta1 induce osteogenic responses in smooth muscle cells. Biochem. Biophys. Res. Commun. 2005, 334:524-532.
68. Simionescu A., Simionescu D.T., Vyavahare N.R. Osteogenic responses in fibroblasts activated by elastin degradation products and transforming growth factor-beta1: role of myofibroblasts in vascular calcification. Am. J. Pathol. 2007, 171:116-123.
69. Safar M.E., Boudier H.S. Vascular development, pulse pressure, and the mechanisms of hypertension. Hypertension 2005, 46:205-209.
70. O'Rourke M.F., Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J. Am. Coll. Cardiol. 2007, 50:1-13.
71. Greenwald S.E. Ageing of the conduit arteries. J. Pathol. 2007, 211:157-172.
72. Price P.A., Buckley J.R., Williamson M.K. The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J. Nutr. 2001, 131:2910-2915.
73. Price P.A., Faus S.A., Williamson M.K. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler. Thromb. Vasc. Biol. 2001, 21:817-824.
74. Price P.A., Chan W.S., Jolson D.M., Williamson M.K. The elastic lamellae of devitalized arteries calcify when incubated in serum: evidence for a serum calcification factor. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1079-1085.
75. Yang H., Curinga G., Giachelli C.M. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney. Int. 2004, 66:2293-2299.
76. Jono S., Nishizawa Y., Shioi A., Morii H. Parathyroid hormone-related peptide as a local regulator of vascular calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 1997, 17:1135-1142.
77. S.L. Cheng, J.S. Shao, L.R. Halstead, K. Distelhorst, O. Sierra, D.A. Towler, Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis. Circ. Res. 107 (2010) 271-282.
78. Li X., Yang H.Y., Giachelli C.M. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 2008, 199:271-277.
79. Li X., Giachelli C.M. Sodium-dependent phosphate cotransporters and vascular calcification. Curr. Opin. Nephrol. Hypertens. 2007, 16:325-328.
80. Li X., Yang H.Y., Giachelli C.M. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ. Res. 2006, 98:905-912.
81. Villa-Bellosta R., Levi M., Sorribas V. Vascular smooth muscle cell calcification and SLC20 inorganic phosphate transporters: effects of PDGF, TNF-alpha, and Pi. Pflugers. Arch. 2009, 458:1151-1161.
82. Qin X., Corriere M.A., Matrisian L.M., Guzman R.J. Matrix metalloproteinase inhibition attenuates aortic calcification. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1510-1516.
83. Aikawa E., Aikawa M., Libby P., Figueiredo J.L., Rusanescu G., Iwamoto Y., et al. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation 2009, 119:1785-1794.
84. Boxer R.S., Wang Z., Walsh S.J., Hager D., Kenny A.M. The utility of the 6-minute walk test as a measure of frailty in older adults with heart failure. Am. J. Geriatr. Cardiol. 2008, 17:7-12.
85. Ginde A.A., Scragg R., Schwartz R.S., Camargo C.A. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J. Am. Geriatr. Soc. 2009, 57:1595-1603.
86. Reis J.P., Michos E.D., von Muhlen D., Miller E.R. Differences in vitamin D status as a possible contributor to the racial disparity in peripheral arterial disease. Am. J. Clin. Nutr. 2008, 88:1469-1477.
87. Lane J.S., Magno C.P., Lane K.T., Chan T., Hoyt D.B., Greenfield S. Nutrition impacts the prevalence of peripheral arterial disease in the United States. J. Vasc. Surg. 2008, 48:897-904.
88. Melamed M.L., Muntner P., Michos E.D., Uribarri J., Weber C., Sharma J., et al. Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1179-1185.
89. A.E. Riek, J. Oh, C. Bernal-Mizrachi, Vitamin D regulates macrophage cholesterol metabolism in diabetes. J. Steroid. Biochem. Mol. Biol. 121 (2010) 430-433.
90. Oh J., Weng S., Felton S.K., Bhandare S., Riek A., Butler B., et al. 1,25(OH)2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 2009, 120:687-698.
91. Tarcin O., Yavuz D.G., Ozben B., Telli A., Ogunc A.V., Yuksel M., et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J. Clin. Endocrinol. Metab. 2009, 94:4023-4030.
92. Sugden J.A., Davies J.I., Witham M.D., Morris A.D., Struthers A.D. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet. Med. 2008, 25:320-325.
93. Matsuoka H. Endothelial dysfunction associated with oxidative stress in human. Diabetes. Res. Clin. Pract. 2001, 54(Suppl. 2):S65-S72.
94. Ghiadoni L., Cupisti A., Huang Y., Mattei P., Cardinal H., Favilla S., et al. Endothelial dysfunction and oxidative stress in chronic renal failure. J. Nephrol. 2004, 17:512-519.
95. Loffredo L., Marcoccia A., Pignatelli P., Andreozzi P., Borgia M.C., Cangemi R., et al. Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease. Eur. Heart J. 2007, 28:608-612.
96. Tesauro M., Schinzari F., Rovella V., Melina D., Mores N., Barini A., et al. Tumor necrosis factor-alpha antagonism improves vasodilation during hyperinsulinemia in metabolic syndrome. Diabetes Care 2008, 31:1439-1441.
97. Al-Aly Z., Shao J.S., Lai C.F., Huang E., Cai J., Behrmann A., et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2589-2596.
98. Lai C.F., Seshadri V., Huang K., Shao J.S., Cai J., Vattikuti R., et al. An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ. Res. 2006, 98:1479-1489.
99. Zittermann A., Frisch S., Berthold H.K., Gotting C., Kuhn J., Kleesiek K., et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am. J. Clin. Nutr. 2009, 89:1321-1327.
100. Schleithoff S.S., Zittermann A., Tenderich G., Berthold H.K., Stehle P., Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 2006, 83:754-759.
101. Leopold J.A., Loscalzo J. Oxidative enzymopathies and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1332-1340.
102. Towler D.A. Oxidation, inflammation, and aortic valve calcification peroxide paves an osteogenic path. J. Am. Coll. Cardiol. 2008, 52:851-854.
103. Wu-Wong J.R., Noonan W., Nakane M., Brooks K.A., Segreti J.A., Polakowski J.S. Cox B Vitamin D receptor activation mitigates the impact of uremia on endothelial function in the 5/6 nephrectomized rats. Int. J. Endocrinol. 2010, 2010:625852.
104. Mancuso P., Rahman A., Hershey S.D., Dandu L., Nibbelink K.A., Simpson R.U. 1,25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+) rats independent of changes in serum leptin. J. Cardiovasc. Pharmacol. 2008, 51:559-564.
105. Patel S., Simpson R.U., Hsu C.H. Calcitriol synthesis is decreased in spontaneously hypertensive rats. Kidney Int. 1988, 34:224-228.
106. Borges A.C., Feres T., Vianna L.M., Paiva T.B. Effect of cholecalciferol treatment on the relaxant responses of spontaneously hypertensive rat arteries to acetylcholine. Hypertension 1999, 34:897-901.
107. Suzuki Y., Ichiyama T., Ohsaki A., Hasegawa S., Shiraishi M., Furukawa S. Anti-inflammatory effect of 1alpha,25-dihydroxyvitamin D(3) in human coronary arterial endothelial cells: implication for the treatment of Kawasaki disease. J. Steroid Biochem. Mol. Biol. 2009, 113:134-138.
108. Martinesi M., Bruni S., Stio M., Treves C. 1,25-Dihydroxyvitamin D3 inhibits tumor necrosis factor-alpha-induced adhesion molecule expression in endothelial cells. Cell Biol. Int. 2006, 30:365-375.
109. Talmor Y., Golan E., Benchetrit S., Bernheim J., Klein O., Green J., et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am. J. Physiol. Renal. Physiol. 2008, 294:F1059-F1064.
110. Zehnder D., Bland R., Chana R.S., Wheeler D.C., Howie A.J., Williams M.C., et al. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J. Am. Soc. Nephrol. 2002, 13:621-629.
111. Wang H.D., Xu S., Johns D.G., Du Y., Quinn M.T., Cayatte A.J., et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ. Res. 2001, 88:947-953.
112. Wang H.D., Johns D.G., Xu S., Cohen R.A. Role of superoxide anion in regulating pressor and vascular hypertrophic response to angiotensin II. Am. J. Physiol. Heart. Circ. Physiol. 2002, 282:H1697-H1702.
113. An S.J., Boyd R., Zhu M., Chapman A., Pimentel D.R., Wang H.D. NADPH oxidase mediates angiotensin II-induced endothelin-1 expression in vascular adventitial fibroblasts. Cardiovasc. Res. 2007, 75:702-709.
114. Flores J., Kunihara T., Shiiya N., Nishibe T., Kudo F., Yasuda K. Inhibition of intimal/medial hyperplasia by perindopril in canine vein grafts. Ann. Vasc. Surg. 2005, 19:499-506.
115. Rey F.E., Pagano P.J. The reactive adventitia: fibroblast oxidase in vascular function. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1962-1971.
116. Guzik T.J., Hoch N.E., Brown K.A., McCann L.A., Rahman A., Dikalov S., et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 2007, 204:2449-2460.
117. Guzik T.J., Marvar P.J., Czesnikiewicz-Guzik M., Korbut R. Perivascular adipose tissue as a messenger of the brain-vessel axis: role in vascular inflammation and dysfunction. J. Physiol. Pharmacol. 2007, 58:591-610.
118. Peterson C.A., Heffernan M.E. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J. Inflamm. (Lond.) 2008, 5:10.
119. X. Li, M.Y. Speer, H. Yang, J. Bergen, C.M. Giachelli, Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin. Arterioscler Thromb. Vasc. Biol. 30 (2010) 321-326.
120. Scatena M., Liaw L., Giachelli C.M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2302-2309.
121. Jono S., Peinado C., Giachelli C.M. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J. Biol. Chem. 2000, 275:20197-20203.
122. Aihara K., Azuma H., Akaike M., Ikeda Y., Yamashita M., Sudo T., et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J. Biol. Chem. 2004, 279:35798-35802.
123. Tintut Y., Patel J., Territo M., Saini T., Parhami F., Demer L.L. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation 2002, 105:650-655.
124. Nadra I., Mason J.C., Philippidis P., Florey O., Smythe C.D., McCarthy G.M., et al. Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways: a vicious cycle of inflammation and arterial calcification?. Circ. Res. 2005, 96:1248-1256.
125. Steitz S.A., Speer M.Y., McKee M.D., Liaw L., Almeida M., Yang H., et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am. J. Pathol. 2002, 161:2035-2046.
126. Bas A., Lopez I., Perez J., Rodriguez M., Aguilera-Tejero E. Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J. Bone Miner. Res. 2006, 21:484-490.
127. Wilke R.A., Simpson R.U., Mukesh B.N., Bhupathi S.V., Dart R.A., Ghebranious N.R., et al. Genetic variation in CYP27B1 is associated with congestive heart failure in patients with hypertension. Pharmacogenomics 2009, 10:1789-1797.
128. A.G. Pittas, B. Dawson-Hughes, Vitamin D and diabetes. J. Steroid. Biochem. Mol. Biol. 121 (2010) 425-429.
129. Pittas A.G., Harris S.S., Stark P.C., Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 2007, 30:980-986.
130. M.D. Witham, L.J. Crighton, N.D. Gillespie, A.D. Struthers, M.E. McMurdo, The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial, Circ. Heart Fail 3 (2010) 195-201.
131. Boxer R.S., Dauser D.A., Walsh S.J., Hager W.D., Kenny A.M. The association between vitamin D and inflammation with the 6-minute walk and frailty in patients with heart failure. J. Am. Geriatr. Soc. 2008, 56:454-461.
132. Armas L.A., Hollis B.W., Heaney R.P. Vitamin D2 is much less effective than vitamin D3 in humans. J. Clin. Endocrinol. Metab. 2004, 89:5387-5391.
133. Romagnoli E., Mascia M.L., Cipriani C., Fassino V., Mazzei F., D'Erasmo E., et al. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J. Clin. Endocrinol. Metab. 2008, 93:3015-3020.
134. Hsia J., Heiss G., Ren H., Allison M., Dolan N.C., Greenland P., et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007, 115:846-854.
135. M.J. Bolland, A. Avenell, J.A. Baron, A. Grey, G.S. Maclennan, G.D. Gamble, I.R. Reid, Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341 (2010) c3691.
136. Jackson R.D., LaCroix A.Z., Gass M., Wallace R.B., Robbins J., Lewis C.E., et al. Calcium plus vitamin D supplementation and the risk of fractures. N. Engl. J. Med. 2006, 354:669-683.
137. Large trial will test vitamin D and omega-3s. Harv. Womens Health Watch 2009, 17:7.
138. de Boer I.H., Kestenbaum B., Shoben A.B., Michos E.D., Sarnak M.J., Siscovick D.S. 25-Hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J. Am. Soc. Nephrol. 2009, 20:1805-1812.
139. Guzman R.J., Brinkley D.M., Schumacher P.M., Donahue R.M., Beavers H., Qin X. Tibial artery calcification as a marker of amputation risk in patients with peripheral arterial disease. J. Am. Coll. Cardiol. 2008, 51:1967-1974.
140. T.S. Polonsky, R.L. McClelland, N.W. Jorgensen, D.E. Bild, G.L. Burke, A.D. Guerci, et al., Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 303 (2010) 1610-1616.
141. Keller C., Katz R., Cushman M., Fried L.F., Shlipak M. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol. 2008, 9:9.
142. B. I. Freedman, L. E. Wagenknecht, K. G. Hairston, D. W. Bowden , J. J. Carr , R. C. Hightower, et al., Vitamin D, adiposity, and calcified atherosclerotic plaque in African-Americans. J. Clin. Endocrinol. Metab. 95 (2010) 1076-1083.
143. Wagenknecht L.E., Langefeld C.D., Carr J.J., Riley W., Freedman B.I., Moossavi S., et al. Race-specific relationships between coronary and carotid artery calcification and carotid intimal medial thickness. Stroke 2004, 35:e97-e99.
144. Jones G. Pharmacokinetics of vitamin D toxicity. Am. J. Clin. Nutr. 2008, 88:582S-586S.
145. Cheng J.B., Levine M.A., Bell N.H., Mangelsdorf D.J., Russell D.W. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc. Natl. Acad. Sci. USA 2004, 101:7711-7715.
146. Haddad J.G. Transport of vitamin D metabolites. Clin. Orthop. Relat. Res. 1979, 249-261.
147. Ritter C.S., Armbrecht H.J., Slatopolsky E., Brown A.J. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int. 2006, 70:654-659.
148. Hewison M., Kantorovich V., Liker H.R., Van Herle A.J., Cohan P., Zehnder D., et al. Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. J. Bone Miner. Res. 2003, 18:579-582.
149. Bonnema S.J., Moller J., Marving J., Kvetny J. Sarcoidosis causes abnormal seasonal variation in 1,25-dihydroxy-cholecalciferol. J. Intern. Med. 1996, 239:393-398.
150. Haddad J.G., Hillman L., Rojanasathit S. Human serum binding capacity and affinity for 25-hydroxyergocalciferol and 25-hydroxycholecalciferol. J. Clin. Endocrinol. Metab. 1976, 43:86-91.
151. Haddad J.G., Walgate J. 25-Hydroxyvitamin D transport in human plasma. Isolation and partial characterization of calcifidiol-binding protein. J. Biol. Chem. 1976, 251:4803-4809.
152. Cooke N.E., Haddad J.G. Vitamin D binding protein (Gc-globulin). Endocr. Rev. 1989, 10:294-307.
153. Safadi F.F., Thornton P., Magiera H., Hollis B.W., Gentile M., Haddad J.G., et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J. Clin. Invest. 1999, 103:239-251.
154. O'Neill W.C. The fallacy of the calcium-phosphorus product. Kidney Int. 2007, 72:792-796.
155. Demer L.L., Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation 2008, 117:2938-2948.
156. London G.M., Guerin A.P., Marchais S.J., Metivier F., Pannier B., Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol. Dial. Transplant. 2003, 18:1731-1740.
157. Ishimura E., Okuno S., Kitatani K., Kim M., Shoji T., Nakatani T., et al. Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patients-importance of glycaemic control. Diabetologia 2002, 45:1446-1448.
158. Isakova T., Gutierrez O., Shah A., Castaldo L., Holmes J., Lee H., et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J. Am. Soc. Nephrol. 2008, 19:615-623.
159. Reynolds J.L., Joannides A.J., Skepper J.N., McNair R., Schurgers L.J., Proudfoot D., et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J. Am. Soc. Nephrol. 2004, 15:2857-2867.
160. Kyriazis J., Katsipi I., Stylianou K., Jenakis N., Karida A., Daphnis E. Arterial stiffness alterations during hemodialysis: the role of dialysate calcium. Nephron. Clin. Pract. 2007, 106:c34-c42.
161. Reynolds J.L., Skepper J.N., McNair R., Kasama T., Gupta K., Weissberg P.L., et al. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J. Am. Soc. Nephrol. 2005, 16:2920-2930.
162. Tanimura A., McGregor D.H., Anderson H.C. Matrix vesicles in atherosclerotic calcification. Proc. Soc. Exp. Biol. Med. 1983, 172:173-177.
163. Shroff R.C., McNair R., Figg N., Skepper J.N., Schurgers L., Gupta A., et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008, 118:1748-1757.
164. Yao Y., Shahbazian A., Bostrom K.I. Proline and gamma-carboxylated glutamate residues in matrix Gla protein are critical for binding of bone morphogenetic protein-4. Circ. Res. 2008, 102:1065-1074.
165. Rogers N.M., Coates P.T. Calcific uraemic arteriolopathy: an update. Curr. Opin. Nephrol. Hypertens. 2008, 17:629-634.
166. Rogers N.M., Teubner D.J., Coates P.T. Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin. Dial. 2007, 20:150-157.
167. Schafer C., Heiss A., Schwarz A., Westenfeld R., Ketteler M., Floege J., et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J. Clin. Invest. 2003, 112:357-366.
168. Shao J.S., Cai J., Towler D.A. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1423-1430.
169. J.S. Shao, S.L. Cheng, J. Sadhu, D.A. Towler, Inflammation and the osteogenic regulation of vascular calcification: a review and perspective, Hypertension 55 579-592.
170. Cohen M.M. The new bone biology: pathologic, molecular, and clinical correlates. Am. J. Med. Genet. A. 2006, 140:2646-2706.
171. Mohler E.R., Gannon F., Reynolds C., Zimmerman R., Keane M.G., Kaplan F.S. Bone formation and inflammation in cardiac valves. Circulation 2001, 103:1522-1528.
172. Khosla S., Eghbali-Fatourechi G.Z. Circulating cells with osteogenic potential. Ann. NY. Acad. Sci. 2006, 1068:489-497.
173. Johnson K., Polewski M., van Etten D., Terkeltaub R. Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/- mice. Arterioscler. Thromb. Vasc. Biol. 2005, 25:686-691.
174. Morony S., Tintut Y., Zhang Z., Cattley R.C., Van G., Dwyer D., et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008, 117:411-420.
175. Miller J.D., Chu Y., Brooks R.M., Richenbacher W.E., Pena-Silva R., Heistad D.D. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J. Am. Coll. Cardiol. 2008, 52:843-850.
176. Parhami F., Morrow A.D., Balucan J., Leitinger N., Watson A.D., Tintut Y., et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vasc. Biol. 1997, 17:680-687.
177. Panizo S., Cardus A., Encinas M., Parisi E., Valcheva P., Lopez-Ongil S., et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ. Res. 2009, 104:1041-1048.
178. Byon C.H., Javed A., Dai Q., Kappes J.C., Clemens T.L., Darley-Usmar V.M., et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J. Biol. Chem. 2008, 283:15319-15327.
179. Bindels R.J. Molecular pathophysiology of renal calcium handling. Kidney Blood Press Res. 2000, 23:183-184.
180. Winer K.K., Ko C.W., Reynolds J.C., Dowdy K., Keil M., Peterson D., et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J. Clin. Endocrinol. Metab. 2003, 88:4214-4220.
181. Tan A.U., Levine B.S., Mazess R.B., Kyllo D.M., Bishop C.W., Knutson J.C., et al. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int. 1997, 51:317-323.
182. Vervaet B.A., D'Haese P.C., De Broe M.E., Verhulst A. Crystalluric and tubular epithelial parameters during the onset of intratubular nephrocalcinosis: illustration of the "fixed particle" theory in vivo. Nephrol. Dial. Transplant. 2009, 24:3659-3668.
183. Vervaet B.A., Verhulst A., Dauwe S.E., De Broe M.E., D'Haese P.C. An active renal crystal clearance mechanism in rat and man. Kidney Int. 2009, 75:41-51.
184. Sakhaee K. Recent advances in the pathophysiology of nephrolithiasis. Kidney Int. 2009, 75:585-595.
185. Stoller M.L., Low R.K., Shami G.S., McCormick V.D., Kerschmann R.L. High resolution radiography of cadaveric kidneys: unraveling the mystery of Randall's plaque formation. J. Urol. 1996, 156:1263-1266.
186. M.C. Hu, M. Shi, J. Zhang, J. Pastor, T. Nakatani, B. Lanske, et al., Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 24 (2010) 3438-3450.
187. Razzaque M.S. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat. Rev. Endocrinol. 2009, 5:611-619.
188. Razzaque M.S., Lanske B. Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends. Mol. Med. 2006, 12:298-305.
189. Fukumoto S., Martin T.J. Bone as an endocrine organ. Trends. Endocrinol. Metab. 2009, 20:230-236.
190. Goetz R., Beenken A., Ibrahimi O.A., Kalinina J., Olsen S.K., Eliseenkova A.V., et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell Biol. 2007, 27:3417-3428.
191. Samadfam R., Richard C., Nguyen-Yamamoto L., Bolivar I., Goltzman D. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 2009, 150:4835-4845.
192. Krajisnik T., Bjorklund P., Marsell R., Ljunggren O., Akerstrom G., Jonsson K.B., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J. Endocrinol. 2007, 195:125-131.
193. Benet-Pages A., Orlik P., Strom T.M., Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 2005, 14:385-390.
194. Lammoglia J.J., Mericq V. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer. Horm. Res. 2009, 71:178-184.
195. Ohnishi M., Nakatani T., Lanske B., Razzaque M.S. In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin D levels. Circ. Cardiovasc. Genet. 2009, 2:583-590.
196. Sitara D., Razzaque M.S., St-Arnaud R., Huang W., Taguchi T., Erben R.G., et al. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am. J. Pathol. 2006, 169:2161-2170.
197. Razzaque M.S., Sitara D., Taguchi T., St-Arnaud R., Lanske B. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. Faseb. J. 2006, 20:720-722.
198. Razzaque M.S., St-Arnaud R., Taguchi T., Lanske B. FGF-23, vitamin D and calcification: the unholy triad. Nephrol. Dial. Transplant. 2005, 20:2032-2035.
199. Price P.A., Omid N., Than T.N., Williamson M.K. The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif. Tissue Int. 2002, 71:356-363.
200. Alexander R.T., Woudenberg-Vrenken T.E., Buurman J., Dijkman H., van der Eerden B.C., van Leeuwen J.P., et al. Klotho prevents renal calcium loss. J. Am. Soc. Nephrol. 2009, 20:2371-2379.
201. Roos M., Lutz J., Salmhofer H., Luppa P., Knauss A., Braun S., et al. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin. Endocrinol. (Oxf.) 2008, 68:660-665.
202. Lee M., Partridge N.C. Parathyroid hormone signaling in bone and kidney. Curr. Opin. Nephrol. Hypertens. 2009, 18:298-302.
203. London G.M., Marty C., Marchais S.J., Guerin A.P., Metivier F., de Vernejoul M.C. Arterial calcifications and bone histomorphometry in end-stage renal disease. J. Am. Soc. Nephrol. 2004, 15:1943-1951.
204. Shao J.S., Cheng S.L., Charlton-Kachigian N., Loewy A.P., Towler D.A. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J. Biol. Chem. 2003, 278:50195-50202.
205. Sebastian E.M., Suva L.J., Friedman P.A. Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure. Bone 2008, 43:1022-1030.
206. Schlieper G., Brandenburg V., Ketteler M., Floege J. Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat. Rev. Nephrol. 2009, 5:539-543.
207. Selby P.L., Davies M., Marks J.S., Mawer E.B. Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate. Clin. Endocrinol. (Oxf.) 1995, 43:531-536.
208. Gurkan F., Davutoglu M., Bosnak M., Ece A., Dikici B., Bilici M., et al. Pamidronate treatment in acute vitamin D intoxication. J. Endocrinol. Invest. 2004, 27:680-682.
209. Hatun S., Cizmecioglu F. Use of alendronate in the treatment of vitamin D intoxication in infants. Turk. J. Pediatr. 2005, 47:373-375.
210. Song G.J., Fiaschi-Taesch N., Bisello A. Endogenous parathyroid hormone-related protein regulates the expression of PTH type 1 receptor and proliferation of vascular smooth muscle cells. Mol. Endocrinol. 2009, 23:1681-1690.
211. Martin-Ventura J.L., Blanco-Colio L.M., Aparicio C., Ortega L., Esbrit P., Egido J. LDL induces parathyroid hormone-related protein expression in vascular smooth muscle cells: modulation by simvastatin. Atherosclerosis 2008, 198:264-271.
212. Fiaschi-Taesch N., Sicari B., Ubriani K., Cozar-Castellano I., Takane K.K., Stewart A.F. Mutant parathyroid hormone-related protein, devoid of the nuclear localization signal, markedly inhibits arterial smooth muscle cell cycle and neointima formation by coordinate up-regulation of p15Ink4b and p27kip1. Endocrinology 2009, 150:1429-1439.
213. Vieth R. Vitamin D toxicity, policy, and science. J. Bone. Miner. Res. 2007, 22(Suppl. 2):V64-V68.
214. McKiernan F.E., Wiley C. Vitamin D2, vitamin D3, and the tolerable upper intake level. J. Bone. Miner. Res. 2008, 23:2060-2061.
215. Armas L.A., Dowell S., Akhter M., Duthuluru S., Huerter C., Hollis B.W., et al. Ultraviolet-B radiation increases serum 25-hydroxyvitamin D levels: the effect of UVB dose and skin color. J. Am. Acad. Dermatol. 2007, 57:588-593.
216. Iqbal J., Hussain M.M. Intestinal lipid absorption. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E1183-E1194.
217. K. Akat, J.J. Kaden, F. Schmitz, S. Ewering, A. Anton, S. Klomfass, et al., Calcium metabolism in adults with severe aortic valve stenosis and preserved renal function. Am. J. Cardiol. 105 (2010) 862-864.
218. Linhartova K., Veselka J., Sterbakova G., Racek J., Topolcan O., Cerbak R. Parathyroid hormone and vitamin D levels are independently associated with calcific aortic stenosis. Circ. J. 2008, 72:245-250.
219. Bilezikian J.P., Khan A.A., Potts J.T. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J. Clin. Endocrinol. Metab. 2009, 94:335-339.
220. Kilpinen-Loisa P., Nenonen H., Pihko H., Makitie O. High-dose vitamin D supplementation in children with cerebral palsy or neuromuscular disorder. Neuropediatrics 2007, 38:167-172.
221. Ammenti A., Pelizzoni A., Cecconi M., Molinari P.P., Montini G. Nephrocalcinosis in children: a retrospective multi-centre study. Acta Paediatr. 2009, 98:1628-1631.
222. Alam M.U., Kirton J.P., Wilkinson F.L., Towers E., Sinha S., Rouhi M., et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc. Res. 2009, 81:260-268.
223. Raggi P., James G., Burke S.K., Bommer J., Chasan-Taber S., Holzer H., et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J. Bone Miner. Res. 2005, 20:764-772.
224. Nakamura S., Ishibashi-Ueda H., Niizuma S., Yoshihara F., Horio T., Kawano Y. Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin. J. Am. Soc. Nephrol. 2009, 4:1892-1900.
225. Shara N.M., Resnick H.E., Lu L., Xu J., Vupputuri S., Howard B.V., et al. Decreased GFR estimated by MDRD or Cockcroft-Gault equation predicts incident CVD: the strong heart study. J. Nephrol. 2009, 22:373-380.
226. Bolland M.J., Barber P.A., Doughty R.N., Mason B., Horne A., Ames R., et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008, 336:262-266.
227. Zerhouni E.A. US biomedical research: basic, translational, and clinical sciences. JAMA 2005, 294:1352-1358.
228. D. Riccardi, E.M. Brown, Physiology and pathophysiology of the calcium-sensing receptor in the kidney, Am. J. Physiol. Renal. Physiol. 298 (2010) F485-F499.
229. Ishibashi S., Brown M.S., Goldstein J.L., Gerard R.D., Hammer R.E., Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 1993, 92:883-893.
230. W. Chang, C. Tu, T.H. Chen, D. Bikle, D. Shoback, The extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development, Sci. Signal 1 (2008) ra1.
231. Ruat M., Molliver M.E., Snowman A.M., Snyder S.H. Calcium sensing receptor: molecular cloning in rat and localization to nerve terminals. Proc. Natl. Acad. Sci. USA 1995, 92:3161-3165.
232. Molostvov G., Bland R., Zehnder D. Expression and role of the calcium-sensing receptor in the blood vessel wall. Curr. Pharm. Biotechnol. 2009, 10:282-288.
233. Molostvov G., Fletcher S., Bland R., Zehnder D. Extracellular calcium-sensing receptor mediated signalling is involved in human vascular smooth muscle cell proliferation and apoptosis. Cell. Physiol. Biochem. 2008, 22:413-422.
234. Molostvov G., James S., Fletcher S., Bennett J., Lehnert H., Bland R., et al. Extracellular calcium-sensing receptor is functionally expressed in human artery. Am. J. Physiol. Renal Physiol. 2007, 293:F946-F955.
235. Smajilovic S., Tfelt-Hansen J. Novel role of the calcium-sensing receptor in blood pressure modulation. Hypertension 2008, 52:994-1000.
236. Neunteufl T., Heher S., Prager G., Katzenschlager R., Abela C., Niederle B., et al. Effects of successful parathyroidectomy on altered arterial reactivity in patients with hypercalcaemia: results of a 3-year follow-up study. Clin. Endocrinol. (Oxf.) 2000, 53:229-233.
237. Henley C., Colloton M., Cattley R.C., Shatzen E., Towler D.A., Lacey D., et al. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol. Dial. Transplant. 2005, 20:1370-1377.
238. Hough T.A., Bogani D., Cheeseman M.T., Favor J., Nesbit M.A., Thakker R.V., et al. Activating calcium-sensing receptor mutation in the mouse is associated with cataracts and ectopic calcification. Proc. Natl. Acad. Sci. USA 2004, 101:13566-13571.
239. Winkelmann B.R., Marz W., Boehm B.O., Zotz R., Hager J., Hellstern P., et al. Rationale and design of the LURIC study - a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001, 2:S1-73.
240. Marz W., Seelhorst U., Wellnitz B., Tiran B., Obermayer-Pietsch B., Renner W., et al. Alanine to serine polymorphism at position 986 of the calcium-sensing receptor associated with coronary heart disease, myocardial infarction, all-cause, and cardiovascular mortality. J. Clin. Endocrinol. Metab. 2007, 92:2363-2369.
241. A. Covic, L. Voroneanu, D. Goldsmith, The effects of vitamin D therapy on left ventricular structure and function - are these the underlying explanations for improved CKD patient survival? Nephron. Clin. Pract. 116 (2010) c187-c195.
242. Riordan M., Rylance G., Berry K. Poisoning in children 3: common medicines. Arch. Dis. Child 2002, 87:400-402.
243. Freundlich M., Quiroz Y., Zhang Z., Zhang Y., Bravo Y., Weisinger J.R., et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008, 74:1394-1402.
244. V. Shalhoub, E. Shatzen, S. Ward, J.I. Young, M. Boedigheimer, Twehues L., et al., Chondro/osteoblastic and cardiovascular gene modulation in human artery smooth muscle cells that calcify in the presence of phosphate and calcitriol or paricalcitol. J. Cell Biochem. 111 (2010) 911-921.
245. F. Silvagno, E. De Vivo, A. Attanasio, V. Gallo, G. Mazzucco, G. Pescarmona, Mitochondrial localization of vitamin D receptor in human platelets and differentiated megakaryocytes, PLoS. One 5: e8670. doi: 10.1371/journal.pone.0008670.
246. Gonzalez Pardo V., Boland R., de Boland A.R. Vitamin D receptor levels and binding are reduced in aged rat intestinal subcellular fractions. Biogerontology 2008, 9:109-118.
247. Sahach V.F., Korkach Iu P., Kotsiuruba A.V., Rudyk O.V., Vavilova H.L. [Mitochondrial permeability transition pore opening inhibition by ecdysterone in heart mitochondria of aging rats]. Fiziol. Zh. 2008, 54:3-10.
248. Rahman A., Hershey S., Ahmed S., Nibbelink K., Simpson R.U. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J. Steroid. Biochem. Mol. Biol. 2007, 103:416-419.
249. M.D. Walker, J.B. Fleischer, M.R. Di Tullio, S. Homma, T. Rundek, E.M. Stein, et al., Cardiac structure and diastolic function in mild primary hyperparathyroidism, J. Clin. Endocrinol. Metab. 95 (2010) 2172-2179.
250. R. Rice, P. Guinto, C. Dowell-Martino, H. He, K. Hoyer, M. Krenz, et al., Cardiac myosin heavy chain isoform exchange alters the phenotype of cTnT-related cardiomyopathies in mouse hearts, J. Mol. Cell Cardiol. 48 (2010) 979-988.
251. O'Connell T.D., Weishaar R.E., Simpson R.U. Regulation of myosin isozyme expression by vitamin D3 deficiency and 1,25-dihydroxyvitamin D3 in the rat heart. Endocrinology 1994, 134:899-905.
252. Wang G.F., Nikovits W., Bao Z.Z., Stockdale F.E. Irx4 forms an inhibitory complex with the vitamin D and retinoic X receptors to regulate cardiac chamber-specific slow MyHC3 expression. J. Biol. Chem. 2001, 276:28835-28841.
253. Simpson R.U., Weishaar R.E. Involvement of 1,25-dihydroxyvitamin D3 in regulating myocardial calcium metabolism: physiological and pathological actions. Cell. Calcium. 1988, 9:285-292.
254. Nibbelink K.A., Tishkoff D.X., Hershey S.D., Rahman A., Simpson R.U. 1,25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyte. J. Steroid Biochem. Mol. Biol. 2007, 103:533-537.
255. Wu-Wong J.R., Nakane M., Ma J., Ruan X., Kroeger P.E. Effects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 2006, 186:20-28.
256. S. Chen, C.S. Law, D.G. Gardner, Vitamin D-dependent suppression of endothelin-induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity. J. Steroid Biochem. Mol. Biol. 118 (2010) 135-141.
257. O'Connell T.D., Simpson R.U. 1,25-Dihydroxyvitamin D3 regulation of myocardial growth and c-myc levels in the rat heart. Biochem. Biophys. Res. Commun. 1995, 213:59-65.
258. Wu-Wong J.R., Nakane M., Ma J. Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. J. Vasc. Res. 2007, 44:11-18.
259. Wu-Wong J.R., Nakane M., Ma J. Effects of vitamin D analogs on the expression of plasminogen activator inhibitor-1 in human vascular cells. Thromb. Res. 2006, 118:709-714.
260. Targher G., Bertolini L., Padovani R., Zenari L., Scala L., Cigolini M., et al. Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. Clin. Endocrinol. (Oxf.) 2006, 65:593-597.
261. Neunteufl T., Katzenschlager R., Abela C., Kostner K., Niederle B., Weidinger F., et al. Impairment of endothelium-independent vasodilation in patients with hypercalcemia. Cardiovasc. Res. 1998, 40:396-401.
262. Kosch M., Hausberg M., Vormbrock K., Kisters K., Rahn K.H., Barenbrock M. Studies on flow-mediated vasodilation and intima-media thickness of the brachial artery in patients with primary hyperparathyroidism. Am. J. Hypertens. 2000, 13:759-764.
263. Kosch M., Hausberg M., Vormbrock K., Kisters K., Gabriels G., Rahn K.H., et al. Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy. Cardiovasc. Res. 2000, 47:813-818.
264. Baykan M., Erem C., Erdogan T., Hacihasanoglu A., Gedikli O., Kiris A., et al. Impairment of flow mediated vasodilatation of brachial artery in patients with primary hyperparathyroidism. Int. J. Cardiovasc. Imaging. 2007, 23:323-328.
265. Hjelmesaeth J., Hofso D., Aasheim E.T., Jenssen T., Moan J., Hager H., et al. Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: a cross-sectional study. Cardiovasc. Diabetol. 2009, 8:7.